No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro

CDK5/p35 is a cyclin-dependent kinase essential for normal neuron function. Proteolysis of the p35 subunit in vivo results in CDK5/p25 that causes neurotoxicity associated with a number of neurodegenerative diseases. Whereas the mechanism by which conversion of p35 to p25 leads to toxicity is unknow...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS Vol. 107; no. 7; pp. 2884 - 2889
Main Authors: Peterson, Dylan W, Ando, D. Michael, Taketa, Daryl A, Zhou, Hongjun, Dahlquist, Fredrick W, Lew, John
Format: Journal Article
Language:English
Published: United States National Academy of Sciences 16-02-2010
National Acad Sciences
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CDK5/p35 is a cyclin-dependent kinase essential for normal neuron function. Proteolysis of the p35 subunit in vivo results in CDK5/p25 that causes neurotoxicity associated with a number of neurodegenerative diseases. Whereas the mechanism by which conversion of p35 to p25 leads to toxicity is unknown, there is common belief that CDK5/p25 is catalytically hyperactive compared to CDK5/p35. Here, we have compared the steady-state kinetic parameters of CDK5/p35 and CDK5/p25 towards both histone H1, the best known substrate for both enzymes, and the microtubule-associated protein, tau, a physiological substrate whose in vivo phosphorylation is relevant to Alzheimer's disease. We show that the kinetics of both enzymes are the same towards either substrate in vitro. Furthermore, both enzymes display virtually identical kinetics towards individual phosphorylation sites in tau monitored by NMR. We conclude that conversion of p35 to p25 does not alter the catalytic efficiency of the CDK5 catalytic subunit by using histone H1 or tau as substrates, and that neurotoxicity associated with CDK5/p25 is unlikely attributable to CDK5 hyperactivation, as measured in vitro.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited* by John A. Carbon, University of California, Santa Barbara, Santa Barbara, CA, and approved December 16, 2009 (received for review November 5, 2009)
Author contributions: D.W.P., D.M.A., and D.A.T. performed research; D.W.P., H.Z., F.W.D., and J.L. analyzed data; H.Z. and F.W.D. contributed new reagents/analytic tools; J.L. designed research; and J.L. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0912718107